Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same

Abstract

Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.

Description

REFERENCE TO RELATED APPLICATION [0001] This application is a continuation-in-part of U.S. patent application Ser. No. 08 / 563,673 filed Nov. 28, 1995, which is a continuation-in-part of U.S. patent application Ser. No. 08 / 414,971 filed Mar. 30, 1995.FIELD OF THE INVENTION [0002] The present invention relates to treatment of drug abuse. More specifically, the present invention relates to methods of treating drug abuse using drug / hapten-carrier conjugates which elicit antibody responses and / or using the antibodies to the drug / hapten-carrier conjugates. BACKGROUND OF THE INVENTION [0003] The prevalence of drug use and abuse worldwide, especially in the United States, has reached epidemic levels. There are a plethora of drugs, both legal and illegal, the abuse of which have become serious public policy issues affecting all strata of society with its obvious medical and social consequences. Some users live in an extremely high risk population associated with poverty and illegal activity....

AI Technical Summary

Benefits of technology

[0019] The present invention overcomes the above mentioned drawbacks and provides methods for treating drug abuse. Using therapeutic compositions, in particular hapten-carrier conjugates, the present invention elicits an immune response in the form of anti-drug antibodies within the addict which upon subsequent exposure to the drug in a vaccinated individual neutralizes the drug so the expected pharmacological effects are diminished, if not eliminated. The present invention provides a therapeutic for drug addiction, particularly cocaine and nicotine addiction, based on vaccination of subjects with a drug/hapten-carrier conjugate, and more particularly, a cocaine-protein or nicotine-protein conjugate. Therapeutic compositions of the invention comprise at least one hapten and at least one T cell epitope-containing carrier which when conjugated to form a hapten-carrier conjugate is capable of stimula...

Problems solved by technology

There are a plethora of drugs, both legal and illegal, the abuse of which have become serious public policy issues affecting all strata of society with its obvious medical and social consequences.

Some users live in an extremely high risk population associated with poverty and illegal activity.

Other users who might classify themselves as recreational users are at risk due to (a) properties of the drug(s) which make them addictive, (b) a predisposition of the user to become a heavy user or (c) a combination of factors including personal circumstances, hardship, environment and accessibility.

Two especially problematic drugs of addiction are cocaine and nicotine.

The cumulative effects of cocaine-associated violent crime, loss in individual productivity, illness, and death is an international problem.

Additional factors contributing to the lack of successful treatment programs is that patterns of cocaine abuse have varied with time.

This behavior leads to addiction, and in some cases, to toxic consequences (Carroll et al., Pharm.

There are only very limited treatments for drugs of abuse and no effective long term treatments for cocaine addiction.

There has also been the use of drugs which potentiate dopaminergic transmission, such as bromocriptine, but the benefits of such drugs are limited in part by toxicity (Taylor et al.

New drugs aimed at replacing methadone for opioid addiction, such as buprenorphine, have also been used based on cross-interference with the dopaminergic system, however only limited clinical study information is available (Fudula et al.

Present therapies used to treat cocaine addicts have at least four major limitations leading to a very high rate of recidivism.

First, and perhaps most fundamentally, the contributing neurochemical events in cocaine abuse and addiction are complex (Carroll et al.

As a result, single acting neuropharmacological approaches, such as inhibition of dopamine uptake, do not appear to be sufficient to overcome addiction.

Second, the drugs currently used in cocaine addiction treatments have significant side-effects themselves, limiting their utility.

Third, drug therapy compliance is problematic among this patient population.

Fourth, because of the complex chemistries involved in pharmacological therapies, many of them may be incompatible with other therapies currently in use or in clinical trials.

Nicotine targets the mesolimbic reward system eventually resulting in physiological dependence.

The lack of effective therapies for nicotine dependence and the poor rate of success in those who try and quit its use indicate that there is a strong need for a new therapy.

These methods, however, suffer from the drawbacks of low penetrance and recidivism of the non-motivated quitter.

Moreover, negative effects have been reported by users of nicotine gum such as mouth irritation, sore jaw muscles, dyspepsia, nausea, hiccups and paresthesia.

While these data provide a demonstration of the feasibility of immunological approaches to addiction therapy, passive immunization as a long term human therapeutic strategy suffers from a number of major drawbacks.

First, if antibodies to be used for passive therapy are from non-human sources or are monoclonal antibodies, these preparations will be seen as foreign proteins by the patient, and there may be a rapid immune response to the foreign antibodies.

This immune response may neutralize the passively administered antibody, blocking its effectiveness and drastically reducing the time of subsequent protection.

In addition, readministration of the same antibody may become problematic, due to the potential induction of a hypersensitivity response.

Thus, when the antibodies are passively administered, rather than induced by immunization, only short term effectiveness can be achieved.

Although this approach is attractive theoretically, it also suffers from some serious problems.

Catalytic antibodies must be administered passively and thus suffer from all of the drawbacks of passive antibody therapy.

Active immunization to generate a catalytic antibody is not feasible, because enzymatic activity is rare among antibodies raised against transition state analogs, and activity does not appear to be detectable in polyclonal preparations.

In addition, the general esterase-like activity of such catalytic antibodies and the uncontrolled nature of the active immune response in genetically diverse individuals makes them potentially toxic molecules, particularly when they are being produced within a human patient.

No effective therapy for drug addiction, especially, cocaine and nicotine addiction, has been developed.

Images